健脾理气方通过调控p53/MUC2信号通路改善功能性消化不良大鼠十二指肠黏膜屏障功能

Jianpi Liqi Formula improved duodenal mucosal barrier function in functional dyspepsia rats by regulating the p53/MUC2 signaling pathway

目的:观察健脾理气方对功能性消化不良(functional dyspepsia,FD)大鼠十二指肠黏膜通透性的影响及对肿瘤蛋白p53(tumor protein p53,p53)和黏液蛋白2(mucin 2,MUC2)通路的调控作用。方法:将18只SD健康雄性大鼠随机分为正常组、模型组、健脾理气方组(6只/组),采用公认的碘乙酰胺灌胃+夹尾刺激法制备FD大鼠模型,模型制备成功后,正常组和模型组大鼠均给予0.9%氯化钠注射液灌胃,健脾理气方组给予健脾理气方水煎剂灌胃。取大鼠十二指肠组织,采用异硫氰酸荧光素-葡聚糖(FITC-Dextran)示踪法检测十二指肠上皮细胞黏膜通透性评价十二指肠肠道屏障功能,并进一步采用实时荧光定量PCR(real-time quantitative PCR,qRT-PCR)和蛋白免疫印迹(Western blot)分别检测p53、MUC2 mRNA含量和蛋白表达情况。结果:模型组大鼠十二指肠黏膜通透性增高,p53、MUC2的mRNA含量均降低,MUC2蛋白表达降低。经健脾理气方治疗后FD大鼠十二指肠黏膜通透性降低,p53 mRNA表达水平显著上升,MUC2的mRNA和蛋白表达水平明显升高。结论:健脾理气方调控p53以增加MUC2的表达,降低十二指肠黏膜通透性,从而恢复十二指肠黏膜屏障功能,可能是该方治疗FD的作用机制之一。

Objective The effect of Jianpi Liqi Formula on the permeability of duodenal mucosa in rats with functional dyspepsia(FD)and its regulatory effect on tumor protein p53(p53)and mucin 2(MUC2)pathways were observed.Methods Eighteen SD healthy male rats were randomly divided into the control group,model group,and Jianpi Liqi formula group(6 animals/group),and FD rat models were prepared by the recognized iodoacetamide gavage and tail stimulation method.Rat duodenal tissue was taken and the luciferin-dextran isothiocyanate-dextran(FITC-Dextran)tracer method was used to detect the permeability of the mucosa of duodenal epithelial cells to evaluate the duodenal intestinal barrier function,and real-time quantitative PCR(qRT-PCR)and Western Blot were used to detect p53,MUC2 mRNA content and protein expression,respectively.Results The duodenal mucosal permeability of rats in the model group increased,the mRNA content of p53 and MUC2 decreased,and the expression of MUC2 protein decreased.After treatment with Jianpi Liqi Formula,the duodenal mucosal permeability of FD rats decreased,the expression level of p53 mRNA increased significantly,and the expression level of mRNA and protein of MUC2 increased significantly.Conclusion Jianpi Liqi Formula regulates p53 to increase the expression of MUC2 and reduce the permeability of the duodenal mucosa,thereby restoring the duodenal mucosal barrier function,which may be one of the mechanisms of action of this prescription for the treatment of FD.